News

Our Healthcare News

Vestar-backed Healthgrades Buys Influence Health

Healthgrades, a Vestar Capital Partners portfolio company, said Jan. 8 that it acquired Influence Health. Financial terms weren’t announced. Influence Health, of Birmingham, Alabama, provides…  

Jan 08 2019

Gurnet Point Capital Completes Tender Offer for Corium International, Transaction Valued in Excess of $500 Million

CAMBRIDGE, Mass.—(BUSINESS WIRE)—Gurnet Point Capital (“Gurnet Point”), a private investment firm focused on the healthcare and life sciences sectors, announced today that it has completed…  

Nov 27 2018

Axogen Advances its Platform for Nerve Repair at Annual Analyst and Investor Day

Updates Value of the Market Opportunity in Existing Applications from $2.2 Billion to $2.7 Billion

Announces Market Development and Clinical Initiatives for Expanded Application in…  

Nov 19 2018

Avance Nerve Graft Receives Regenerative Medicine Advanced Therapy (RMAT) Designation

RMAT Designation reinforces clinical significance of RANGER® registry data and acknowledges the unmet need for improved nerve repair solutions

ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ: AXGN),…  

Oct 29 2018

EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg

The first long-lasting, FDA approved micro-insert for up to three years of continuous control in chronic, non-infectious posterior segment uveitis, the third leading cause of…  

Oct 15 2018

Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares

Total Transaction Valued in Excess of $500 Million, Representing a 50% Premium

Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization…  

Oct 11 2018

EW Healthcare Partners Announces the Appointment of Two Senior Executives

NEW YORK, New York – EW Healthcare Partners (“EW”), a leading healthcare growth equity firm with a global investment practice, has announced the addition of…  

Oct 10 2018

EUSA Pharma Announces Acquisition of Global Rights to SYLVANT (siltuximab) from Janssen Sciences Ireland UC for $115 Million

Acquisition significantly boosts EUSA Pharma’s presence as a global biopharmaceutical company in oncology and rare diseases

SYLVANT is the only FDA and EMA approved treatment…  

Jul 18 2018

AxoGen Chairman and CEO Karen Zaderej Named Entrepreneur of the Year 2018 Award Winner in Florida

ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Ernst & Young (EY)…  

Jun 08 2018



View Legacy Fund news >